Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Mrs. B is a 45 year old premenopausal female who was diagnosed with major depressive disorder 10 years ago and then successfully treated for 12 months with fluoxetine 20 mg daily without significant side effects from therapy. She remained free of depressive symptoms for the next 8-9 years. One year ago, she was diagnosed with estrogen receptor (ER) positive invasive breast cancer and underwent treatment with surgery, followed by chemotherapy, and then radiation therapy. Mrs. B. has been treated with the selective estrogen receptor modulator (SERM) tamoxifen for the past 6 months to reduce her likelihood of breast cancer recurrence. She has tolerated tamoxifen relatively well, except for moderately bothersome hot flashes for which she has received no pharmacologic therapy. Recently, however, she developed recurrent depressive symptoms and sought treatment from her psychiatrist. What pharmacologic agents are effective against both depression and hot flashes in women with breast cancer? Would any of these agents compromise the efficacy of tamoxifen or increase its toxicity through a drug-drug interaction?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Major depression after breast cancer: a review of epidemiology and treatment
Fann, J. R., Thomas-Rich, A. M., Katon, W. J., Cowley, D., Pepping, M., McGregor, B. A., & Gralow, J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.10.008 · Cited by 586
Stearns, V., Beebe, K. L., Iyengar, M., & Dube, E. (2003) · JAMA · doi:10.1001/jama.289.21.2827 · Cited by 496
Self-citationPhase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., Halyard, M. Y., Pruthi, S., Novotny, P. J., & Rummans, T. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1578 · Cited by 473
A 40-Year Perspective on the Prevalence of Depression: The Stirling County Study
Murphy, J. M., Laird, N. M., Monson, R. R., Sobol, A. M., & Leighton, A. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.209 · Cited by 318
Yildiz, A., Guleryuz, S., Ankerst, D. P., Öngür, D., & Renshaw, P. F. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.43 · Cited by 213 · cited 1×
“As noted above, it is unclear whether tamoxifen causes or exacerbates depression, but this agent was recently demonstrated to have antimanic properties in patients with bipolar disorder (10).”
BackgroundNonhormonal Therapies for Menopausal Hot Flashes: Systematic Review and Meta-analysis
Nelson, H. D., Vesco, K. K., Haney, E., Fu, R., Nedrow, A., Miller, J., Nicolaidis, C., Walker, M., & Humphrey, L. (2006) · JAMA · doi:10.1001/jama.295.17.2057 · Cited by 4
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0035 · Cited by 664
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Ramaswami, R., Villarreal, M. D., Pitta, D. M., Carpenter, J. S., Stebbing, J., & Kalesan, B. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3465-5 · Cited by 49
“patients undergoing tamoxifen treatment [37].”
Kisely, S., Alotiby, M. K. N., Protani, M. M., Soole, R., Arnautovska, U., & Siskind, D. (2023) · Psycho-Oncology · doi:10.1002/pon.6120 · Cited by 31
“, paroxetine) may inhibit the metabolism of tamoxifen through inhibition of the cytochrome P450 system (CYP2D6).(60) There may be several explanations for our main findings of reduced or delayed access to guideline appropriate care, including both provider‐ and patient‐based factors.”
Background
Metadata
- Authors
- Henry, N. L., Stearns, V., Flockhart, D. A., Hayes, D. F., & Riba, M.
- Venue
- American Journal of Psychiatry
- Published
- 2008-10
- Volume
- 165
- Issue
- 10
- Pages
- 1251-1255
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2160921900
- Cited by
- 106
- References
- 7
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.